GlassScriptPhysician profile
David Franklin Stein
NPI 1285620237
$196,100.05
in general payments reported to CMS, 2019-2025
44 companies · $34K in 2025
The $34K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65K · 2020: $16K · 2021: $19K · 2022: $20K · 2023: $22K · 2024: $20K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Food and Beverage: $9,109 · Travel and Lodging: $2,166 · Consulting Fee: $968 · Grant: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,065.00 |
| Food and Beverage | $9,109.00 |
| Travel and Lodging | $2,166.25 |
| Consulting Fee | $967.50 |
| Grant | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $117,757.22 | 2019-2025 | Vemlidy, Epclusa |
| Abbvie INC. | $45,226.61 | 2019-2025 | Mavyret, Rinvoq, Skyrizi |
| Madrigal Pharmaceuticals | $21,951.39 | 2025 | Rezdiffra |
| Shionogi INC | $3,397.36 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,878.91 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Takeda Pharmaceuticals U.S.A., INC. | $939.70 | 2019-2025 | Entyvio, Vpriv, Eohilia |
| Intercept Pharmaceuticals, INC. | $543.08 | 2019-2025 | Ocaliva |
| Janssen Biotech, INC. | $452.32 | 2019-2025 | Tremfya, Stelara |
| Pfizer INC. | $429.22 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $297.77 | 2020-2024 | Dificid |
| Celgene Corporation | $278.97 | 2021-2024 | Zeposia |
| Romark Laboratories, Lc | $273.41 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $264.29 | 2021-2023 | Zeposia |
| Olympus America INC. | $249.99 | 2019-2023 | Evis Exera III Video System Center |
| Janssen Scientific Affairs, LLC | $249.66 | 2019 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $213.93 | 2022-2024 | |
| Ardelyx, INC. | $176.12 | 2022-2025 | Ibsrela |
| Allergan, INC. | $165.36 | 2019 | |
| Ironwood Pharmaceuticals, INC | $160.62 | 2019-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $133.43 | 2019-2021 | |
| Viiv Healthcare Company | $108.10 | 2019-2023 | Dovato |
| Daiichi Sankyo INC. | $104.40 | 2022-2024 | Injectafer |
| Exact Sciences Corporation | $95.14 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Amgen INC. | $92.45 | 2024-2025 | Uplizna |
| Redhill Biopharma INC. | $87.95 | 2020-2022 | |
| Cumberland Pharmaceuticals, INC. | $78.36 | 2020-2022 | |
| Novo Nordisk INC | $57.24 | 2025 | Wegovy, Saxenda |
| Ucb, INC. | $53.07 | 2019 | |
| Fresenius Kabi USA, LLC | $48.59 | 2023 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.01 | 2023 | Cyltezo |
| Lilly USA, LLC | $39.81 | 2024-2025 | Omvoh |
| Ethicon US, LLC | $31.89 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $28.80 | 2024 | Dupixent |
| Alnylam Pharmaceuticals INC. | $22.19 | 2023 | Givlaari |
| Orphalan INC | $21.45 | 2024 | Cuvrior |
| Theratechnologies INC. | $21.08 | 2023 | Trogarzo, Egrifta |
| Organon LLC | $19.53 | 2023 | Hadlima |
| Medtronic, INC. | $17.34 | 2023 | Gi Genius |
| Pentax of America, INC. | $16.36 | 2024 | Pentax Medical, Inspira, C2 Cryoballoon |
| Echosens North America, INC. | $15.00 | 2022 | |
| Qol Medical, LLC | $14.92 | 2021 | |
| Eisai INC. | $13.41 | 2021 | |
| Mallinckrodt Hospital Products INC. | $13.24 | 2023 | Terlivaz |
| Alfasigma USA, INC. | $12.36 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.